What do systematic reviews say?

5‐ASA vs no treatment

The review found no eligible studies for this question.

• Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

5‐ASA vs placebo

5‐ASAs probably leads to lower clinical relapse compared with placebo (moderate certainty).

• Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  RR 0.83 [0.72, 0.96]
  5 studies · 730 participants
  Moderate

5‐ASA vs placebo

It is very uncertain whether 5‐ASAs changes endoscopic recurrence compared with placebo (very low certainty).

• Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  RR 0.83 [0.56, 1.24]
  3 studies · 537 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

Summary of findings: cycled probably leads to higher time to next isolation of PA compared with culture‐based antibiotic therapy (moderate certainty).

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  HR 2.04 [1.28, 3.26]
  1 study · 253 participants
  Moderate

Summary of findings: cycled vs culture‐based antibiotic therapy

The review found no eligible studies for this question.

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 131 participants
  Very low

Summary of findings: cycled vs culture‐based antibiotic therapy

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 253 participants
  Moderate

Summary of findings: cycled vs culture‐based antibiotic therapy

The review found no eligible studies for this question.

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

Summary of findings: cycled showed no clear difference in adverse events: severe adverse events (total) compared with culture‐based antibiotic therapy (moderate certainty).

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  RR 0.65 [0.39, 1.11]
  1 study · 253 participants
  Moderate

Summary of findings: cycled vs culture‐based antibiotic therapy

Summary of findings: cycled showed no clear difference in emergence of novel bacteria: isolation of novel gram negative… compared with culture‐based antibiotic therapy (moderate certainty).

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  RR 1 [0.67, 1.5]
  1 study · 253 participants
  Moderate